Chemistry:Lilotomab
From HandWiki
Short description: Murine monoclonal antibody against CD37
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD37 |
| Clinical data | |
| Other names | Tetulomab, HH1 |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
Lilotomab (formerly tetulomab, HH1)[1] is a murine monoclonal antibody against CD37,[2] a glycoprotein which is expressed on the surface of mature human B cells.[3] It was generated at the Norwegian Radium Hospital.[3]
As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA.[2] This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin).[1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.[4]
The satetraxetan structure chelating lutetium-177[5]
References
- ↑ 1.0 1.1 "Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800037665.
- ↑ 2.0 2.1 "Recommended INN List 74". WHO Drug Information 29 (3). 2015. https://www.who.int/medicines/publications/druginformation/issues/74_INN_List.pdf?ua=1.
- ↑ 3.0 3.1 "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opinion on Biological Therapy 14 (5): 651–61. May 2014. doi:10.1517/14712598.2014.890182. PMID 24555705.
- ↑ "EudraCT Number: 2011-000033-36". EU Clinical Trials Registry. https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000033-36/CZ. "Treatment of lymphoma with targeted internal radiation therapy (Betalutin)"
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112". WHO Drug Information 28 (4): 515. 2014. https://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf.
Further reading
- "Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma". Current Radiopharmaceuticals 6 (1): 20–7. March 2013. doi:10.2174/1874471011306010004. PMID 23256748.
 |  |
